GI Cancer: Sequential Treatment Planning in the Community Oncology Setting
Med-IQ Select Med-IQ Select

GI Cancer: Sequential Treatment Planning in the Community Oncology Setting

Please choose a module from the options below. To receive credit and a certificate, you must complete all of the modules in this activity.

Welcome to this Med-IQ Select on sequential treatment planning in the community oncology setting. Med-IQ Select is a unique online educational offering that allows you to pick and choose the content you would like to view—in any order and at your convenience.

To get started, click "view" on any of the modules below. To receive credit and a certificate, you must complete all of the modules.

Complete all of the above modules to earn credit;
0 out of 6 modules complete

Maximum Credits:

Released: 8/9/2019

Expires: 8/8/2020

Overview: Join expert faculty for a 90-minute webcast filmed during a gastrointestinal oncology forum that includes didactic lectures and case-based presentations. This activity is designed to take participants through various decision points to better align clinical factors with treatment decisions in a way that confers optimal patient outcomes throughout the disease continuum; specifically, faculty focus on using biomarkers to determine appropriate treatment planning from first-line through subsequent lines of therapy in colorectal cancer, gastric cancer, and hepatocellular carcinoma.

CME Information:

Tanios S. Bekaii-Saab, MD
Professor of Medicine
Vice Chair and Section Chief, Division of Hematology/Oncology
Department of Internal Medicine
College of Medicine and Science
Leader, Gastrointestinal Cancer Program
Mayo Clinic Cancer Center
Medical Director, Cancer Clinical Research Office
Mayo Clinic
Phoenix, AZ

Johanna Bendell, MD
Chief Development Officer
Director, Drug Development Unit Nashville
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, TN

Axel Grothey, MD
Director GI Cancer Research
West Cancer Center and Research Institute
Memphis, TN

David H. Ilson, MD, PhD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY

Activity Planners
Amy Burdette, PhD
Manager, Educational Strategy and Content
Baltimore, MD

Samantha Gordon
CME Specialist
Baltimore, MD

Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
East Lansing, MI

Learning Objectives
Upon completion, participants should be able to:

  • Use patient characteristics and biomarker profiles to inform treatment decisions for patients with advanced or metastatic gastric and GEJ cancer
  • Select appropriate treatment regimens for patients with advanced or metastatic gastric and GEJ cancer that maximize the benefit of sequential lines of therapy
  • Define the influence of molecular characteristics and primary tumor location on treatment effectiveness in patients with mCRC
  • Optimally select and sequence treatments for patients with mCRC based on multiple clinical factors including molecular characteristics and primary tumor location
  • Discuss the use of prognostic and predictive biomarkers including AFP in HCC
  • Identify patients with advanced HCC who would benefit from individualized treatment approaches

Target Audience
This activity is intended for community oncologists.
Statement of Need
Knowledge related to the genetic nature of gastrointestinal (GI) cancers—specifically metastatic colorectal cancer (CRC), gastric and gastroesophageal junction (GEJ) adenocarcinoma, and hepatocellular carcinoma (HCC)—as well as the use of biomarkers in patients with these cancers when appropriate, is rapidly evolving, requiring community oncologists to stay abreast of emerging evidence to guide treatment planning. Evidence-based guidelines and ongoing research can provide frameworks for determining treatment selection and proper sequencing across multitudes of different combinations of chemotherapy, molecular targeted therapies, anti-angiogenic agents, and immunotherapies; however, the most effective selection and sequence of agents continues to be debated. Focused, contextual education can help community oncologists better understand the role of factors such as patient characteristics and anatomical and molecular profiles of tumors in determining first-line treatment and subsequent lines of therapy.
Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statement
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.
Medium/Method of Participation
This is a 1.5-credit CME activity. To receive credit, read the introductory CME material, complete all of the modules, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Initial Release Date: August 9, 2019
Expiration Date: August 8, 2020
Estimated Time to Complete This Activity: 1 hour and 30 minutes
Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Tanios S. Bekaii-Saab, MD
Consulting fees/advisory boards: AbbVie Inc., Imugene, Immuneering Corporation
Other: ARMO Biosciences, Exelixis, Inc., SillaJen Inc.
Johanna Bendell, MD, has indicated no real or apparent conflicts.
Axel Grothey, MD, has indicated no real or apparent conflicts.

David H. Ilson, MD, PhD
Consulting fees/advisory boards: Amgen, Astellas Pharma US, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffman-La Roche Ltd., Merck & Co., Inc., Pieris Pharmaceuticals, Taiho Pharmaceutical Co, Ltd.
Contracted research: Astellas Pharma US, Merck & Co., Inc., Pieris Pharmaceuticals, Taiho Pharmaceutical Co, Ltd.

The peer reviewers and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information        
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email

System Requirements


  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit:

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit

© 2019 Med-IQ, Inc.


Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email For technical assistance, please refer to our support manual.

We recently updated our Privacy Notice and Terms of Use.